DPP4 and ACE2 in diabetes and COVID-19: Therapeutic targets for cardiovascular complications?
COVID-19 outbreak, caused by severe acute respiratory syndrome (SARS)-CoV-2 coronavirus has become an urgent health and economic challenge. Diabetes is a risk factor for severity and mortality of COVID-19. Recent studies support that COVID-19 has effects beyond the respiratory tract, with vascular c...
| Autores: | , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2020 |
| País: | España |
| Institución: | Universidad Autónoma de Madrid |
| Repositorio: | Biblos-e Archivo. Repositorio Institucional de la UAM |
| Idioma: | inglés |
| OAI Identifier: | oai:repositorio.uam.es:10486/692332 |
| Acceso en línea: | http://hdl.handle.net/10486/692332 https://dx.doi.org/10.3389/fphar.2020.01161 |
| Access Level: | acceso abierto |
| Palabra clave: | ACEi diabetes angiotensin converting enzyme 2 cardiovascular disease COVID-19 dipeptidyl peptidase 4 gliptins SARS-CoV-2 Medicina |
| id |
ES_2d99476f5439684e57a2ef6cd53abbda |
|---|---|
| oai_identifier_str |
oai:repositorio.uam.es:10486/692332 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
DPP4 and ACE2 in diabetes and COVID-19: Therapeutic targets for cardiovascular complications?Valencia, InésPeiró Vallejo, M. ConcepciónLorenzo González, ÓscarSánchez Ferrer, Carlos FélixEckel, JürgenRomacho, TaniaACEidiabetesangiotensin converting enzyme 2cardiovascular diseaseCOVID-19dipeptidyl peptidase 4gliptinsSARS-CoV-2MedicinaCOVID-19 outbreak, caused by severe acute respiratory syndrome (SARS)-CoV-2 coronavirus has become an urgent health and economic challenge. Diabetes is a risk factor for severity and mortality of COVID-19. Recent studies support that COVID-19 has effects beyond the respiratory tract, with vascular complications arising as relevant factors worsening its prognosis, then making patients with previous vascular disease more prone to severity or fatal outcome. Angiotensin-II converting enzime-2 (ACE2) has been proposed as preferred receptor for SARS-CoV-2 host infection, yet specific proteins participating in the virus entry are not fully known. SARS-CoV-2 might use other co-receptor or auxiliary proteins allowing virus infection. In silico experiments proposed that SARS-CoV-2 might bind dipeptidyl peptidase 4 (DPP4/CD26), which was established previously as receptor for MERS-CoV. The renin–angiotensin–aldosterone system (RAAS) component ACE2 and DPP4 are proteins dysregulated in diabetes. Imbalance of the RAAS and direct effect of soluble DPP4 exert deleterious vascular effects. We hypothesize that diabetic patients might be more affected by COVID-19 due to increased presence ACE2 and DPP4 mediating infection and contributing to a compromised vasculature. Here, we discuss the role of ACE2 and DPP4 as relevant factors linking the risk of SARS-CoV-2 infection and severity of COVID-19 in diabetic patients and present an outlook on therapeutic potential of current drugs targeted against RAAS and DPP4 to treat or prevent COVID-19-derived vascular complications. Diabetes affects more than 400 million people worldwide, thus better understanding of how they are affected by COVID-19 holds an important benefit to fight against this disease with pandemic proportionsIV is the recipient of a FPU fellowship (FPU16/02612). TR and JE are supported by KomIT-Center of Competence for Innovative Diabetes Therapy- funded by EFRE-NRW. CP and CS-F are supported by a grant from Plan Nacional de I+D (SAF2017-84776-R)Frontiers MediaDepartamento de FarmacologíaDepartamento de MedicinaFacultad de Medicina20202020-08-07research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10486/692332https://dx.doi.org/10.3389/fphar.2020.01161reponame:Biblos-e Archivo. Repositorio Institucional de la UAMinstname:Universidad Autónoma de MadridInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:repositorio.uam.es:10486/6923322026-06-23T12:46:27Z |
| dc.title.none.fl_str_mv |
DPP4 and ACE2 in diabetes and COVID-19: Therapeutic targets for cardiovascular complications? |
| title |
DPP4 and ACE2 in diabetes and COVID-19: Therapeutic targets for cardiovascular complications? |
| spellingShingle |
DPP4 and ACE2 in diabetes and COVID-19: Therapeutic targets for cardiovascular complications? Valencia, Inés ACEi diabetes angiotensin converting enzyme 2 cardiovascular disease COVID-19 dipeptidyl peptidase 4 gliptins SARS-CoV-2 Medicina |
| title_short |
DPP4 and ACE2 in diabetes and COVID-19: Therapeutic targets for cardiovascular complications? |
| title_full |
DPP4 and ACE2 in diabetes and COVID-19: Therapeutic targets for cardiovascular complications? |
| title_fullStr |
DPP4 and ACE2 in diabetes and COVID-19: Therapeutic targets for cardiovascular complications? |
| title_full_unstemmed |
DPP4 and ACE2 in diabetes and COVID-19: Therapeutic targets for cardiovascular complications? |
| title_sort |
DPP4 and ACE2 in diabetes and COVID-19: Therapeutic targets for cardiovascular complications? |
| dc.creator.none.fl_str_mv |
Valencia, Inés Peiró Vallejo, M. Concepción Lorenzo González, Óscar Sánchez Ferrer, Carlos Félix Eckel, Jürgen Romacho, Tania |
| author |
Valencia, Inés |
| author_facet |
Valencia, Inés Peiró Vallejo, M. Concepción Lorenzo González, Óscar Sánchez Ferrer, Carlos Félix Eckel, Jürgen Romacho, Tania |
| author_role |
author |
| author2 |
Peiró Vallejo, M. Concepción Lorenzo González, Óscar Sánchez Ferrer, Carlos Félix Eckel, Jürgen Romacho, Tania |
| author2_role |
author author author author author |
| dc.contributor.none.fl_str_mv |
Departamento de Farmacología Departamento de Medicina Facultad de Medicina |
| dc.subject.none.fl_str_mv |
ACEi diabetes angiotensin converting enzyme 2 cardiovascular disease COVID-19 dipeptidyl peptidase 4 gliptins SARS-CoV-2 Medicina |
| topic |
ACEi diabetes angiotensin converting enzyme 2 cardiovascular disease COVID-19 dipeptidyl peptidase 4 gliptins SARS-CoV-2 Medicina |
| description |
COVID-19 outbreak, caused by severe acute respiratory syndrome (SARS)-CoV-2 coronavirus has become an urgent health and economic challenge. Diabetes is a risk factor for severity and mortality of COVID-19. Recent studies support that COVID-19 has effects beyond the respiratory tract, with vascular complications arising as relevant factors worsening its prognosis, then making patients with previous vascular disease more prone to severity or fatal outcome. Angiotensin-II converting enzime-2 (ACE2) has been proposed as preferred receptor for SARS-CoV-2 host infection, yet specific proteins participating in the virus entry are not fully known. SARS-CoV-2 might use other co-receptor or auxiliary proteins allowing virus infection. In silico experiments proposed that SARS-CoV-2 might bind dipeptidyl peptidase 4 (DPP4/CD26), which was established previously as receptor for MERS-CoV. The renin–angiotensin–aldosterone system (RAAS) component ACE2 and DPP4 are proteins dysregulated in diabetes. Imbalance of the RAAS and direct effect of soluble DPP4 exert deleterious vascular effects. We hypothesize that diabetic patients might be more affected by COVID-19 due to increased presence ACE2 and DPP4 mediating infection and contributing to a compromised vasculature. Here, we discuss the role of ACE2 and DPP4 as relevant factors linking the risk of SARS-CoV-2 infection and severity of COVID-19 in diabetic patients and present an outlook on therapeutic potential of current drugs targeted against RAAS and DPP4 to treat or prevent COVID-19-derived vascular complications. Diabetes affects more than 400 million people worldwide, thus better understanding of how they are affected by COVID-19 holds an important benefit to fight against this disease with pandemic proportions |
| publishDate |
2020 |
| dc.date.none.fl_str_mv |
2020 2020-08-07 |
| dc.type.none.fl_str_mv |
research article http://purl.org/coar/resource_type/c_2df8fbb1 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/10486/692332 https://dx.doi.org/10.3389/fphar.2020.01161 |
| url |
http://hdl.handle.net/10486/692332 https://dx.doi.org/10.3389/fphar.2020.01161 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Frontiers Media |
| publisher.none.fl_str_mv |
Frontiers Media |
| dc.source.none.fl_str_mv |
reponame:Biblos-e Archivo. Repositorio Institucional de la UAM instname:Universidad Autónoma de Madrid |
| instname_str |
Universidad Autónoma de Madrid |
| reponame_str |
Biblos-e Archivo. Repositorio Institucional de la UAM |
| collection |
Biblos-e Archivo. Repositorio Institucional de la UAM |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869405331668336640 |
| score |
15,301603 |